Skip to main content
XTNT logo

XTNT · Xtant Medical Holdings, Inc.

Track XTNT — free
$0.26 -0.01 (-4.20%)
Market Cap
$38.12M
Shares
140.29M
Volume · Nov 13 181.75K Avg daily vol (3M) 1.67M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.27 Open$0.31 Day$0.26–0.31 52W close$0.27–0.81 Avg vol 30d139K Short int375K · 0.3% of shares · 3.9d Short vol35% Last earningsAug 11, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 16

Latest documents

2026
Nov 16
Quarterly report 10-Q Ended Sep 30
Material weakness persists amid debt covenant pressure

Xtant Medical Holdings reported ineffective disclosure controls due to an inventory valuation material weakness as of September 30, 2026. It lost $16.1 million and used $10.3 million in operating activities during nine months, required covenant amendments, and withdrew 2026 guidance.

Revenue $24.29M ▼ 27.0% Net loss $3.56M Diluted EPS -$0.03
Read from the MD&A section
7 source passages
I have reviewed this quarterly report on Form 10-Q of Xtant Medical Holdings, Inc.; Based upon that evaluation, and as a result of the material weakness in our internal control over financial reporting discussed below, our principal executive officer and principal financial officer concluded that as of September 30, 2026, our disclosure controls and procedures were not effective. More specifically, our controls surrounding our evaluation of inventory net realizable value were insufficient and did not operate at an appropriate level of precision. For the nine months ended September 30, 2026, we had a net loss of $16.1 million and used $10.3 million of cash in operating activities. In March 2026, we entered into the Amendment No. 4s with MidCap. In August 2026, we entered into the Amendment No. 5s, which eliminated the requirement for that quarter and set new minimum net revenue amounts. We have withdrawn our full-year 2026 financial guidance and are not providing revised guidance during the review, which may reduce the information available to investors. Open the document at this passage
Nov 16
Current report 8-K
Strategic review follows second consecutive quarterly guidance miss

Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.

Financial results
6 source passages
Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,” said Stavros Vizirgianakis, Chairman of the Board. Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025. Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. Open the document at this passage
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $23.03M ▼ 35.0% Net loss $9.41M Diluted EPS -$0.07
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$109.53M
Trailing 12 months
Net income (TTM)
−$11.14M
Trailing 12 months
Revenue growth YoY
-35.0%
Year over year
Operating margin
-9.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.6%
Year over year · fewer shares
Price change (1Y)
-58.8%
Trailing year
Short interest
0.3%
Latest settlement · 3.9 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26

TL;DR. Xtant reported Q2 2026 revenue of $23.0M with a net loss of $9.4M and an adjusted EBITDA loss of $2.7M, lowered full-year 2026 revenue guidance to $99–$103M (from $101–$105M), while advancing the Dilon/HEMOBLAST distribution agreement and launching Trivium Shaped.

Bullish
  • + Acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows, adding entry into an estimated $1B hemostatic TAM and a 17-rep specialty Salesforce
  • + Launched Trivium Shaped in May with strong early sales traction, extending the Trivium DBM bone graft portfolio
  • + Hardware revenue was higher than anticipated in Q2, driven by sales of the Corterra spinal fixation system
Bearish
  • − Gross margin compressed to 57.9% from 68.6% due to cessation of high-margin Q-code license revenue, reduced production efficiencies, and higher excess/obsolete inventory charges
  • − Q2 operating expenses rose to $22.5M from $19.7M, driven by a $5.0M exclusivity fee paid to Dilon Technologies

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −14%
below
RSI (14) 38
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −41%
trailing
YTD return −65%
this year
Relative strength −41%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
29 of 33 funds reported for Sep 30 · net -484.0K sh shares · +5 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.27% of shares out · ▲ +24.9% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Squeeze score 48
elevated · 0–100
Fundamentals
Excellent
Revenue growth −18%
Y/Y
Gross margin 158%
expanding
EPS growth +125%
Y/Y
Free cash flow $10.2M
Balance sheet $2.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −66%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the 8-K filed Aug 11, 2026
Full-year guidance · full year 2026 Lowered $99M – $103M
May 13, 2026 $101M – $105M changed to Aug 11, 2026 $99M – $103M
prior FY $133.93M midpoint −24.6% Y/Y
Guided vs delivered · last 3 settled
Full year 2025 revenue full year 2025
guided $131M – $135M
$133.93M In line
Full year 2024 revenue full year 2024
guided $116M – $120M
$117.27M In line
Full year 2023 revenue full year 2023
guided $88M – $91M
$91.3M Beat +2.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
38 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
29 of 33 funds reported for Sep 30 · net -484.0K sh shares · +5 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.27% of shares out · ▲ +24.9% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -39% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Non-GAAP Adjusted EBITDA non-GAAP -4.26M Six Months Ended June 30, 2026 —
Non-GAAP adjusted EBITDA loss non-GAAP 2.7M second quarter of 2026 —
Non-GAAP Adjusted EBITDA/Total Revenue non-GAAP -11.6% Three Months Ended June 30, 2026 —
Non-GAAP EBITDA non-GAAP -10.44M Six Months Ended June 30, 2026 —
Non-GAAP EBITDA/Total Revenue non-GAAP -36% Three Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
XTNT
Xtant Medical Holdings, Inc.
this stock
$38.12M -65.2% -17.5% — 0.3%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
33
% held
56.9%
Reported
29 of 33
Top holder
Nantahala Capital Managem…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
375.3K
Days to cover
3.9d
Change
+74.8K sh
View
Short Volume
Short vol %
35%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
3.4K
Value
$1.1K
As of
Oct 6, 2026
View
Off-Exchange
Off-exchange %
53.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$133.9M
Net income (FY)
$5.0M
EPS diluted
$0.03
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
15

Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.

View
Exempt Offerings
Offering
$5.0M
Filed
Aug 12, 2024
View
Earnings & Events
Webcasts
Last webcast
Aug 11, 2026
View
Investor Relations
Latest news
Xtant Medical Reports Third Quart…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
XTNT -6.1% -5.2% -40.9% -3.0% -65.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -8.7% -4.1% -41.4% -2.9% -75.8%
Key facts CIK 1453593 CUSIP 98420P308 13F (30d) 29 filings 23 filers Visit website Investor relations